Partnership between GSK and Verily to develop bioelectronic medicines.
Developing a platform to treat chronic inflammation via the vagus nerve.
United States · Research Lab
Research arm of Northwell Health, home to the Institute of Bioelectronic Medicine.
Global medical device company focused on closed-loop spinal cord stimulation.
Bioelectronic medicine company transforming the standard of care for chronic disease.
UK · Company
Global medical technology company known for Vagus Nerve Stimulation (VNS).
Creates therapies to restore movement, independence, and health in people with spinal cord injury.
Wearable bioelectronic medicine for opioid withdrawal.
Bioelectronic medicine devices are therapeutic systems that use electrical stimulation of nerves to treat diseases by modulating the body's inflammatory and immune responses. These platforms combine flexible electrodes that interface with nerves, AI-powered controllers that adjust stimulation based on biomarker feedback, and integrated sensors that monitor inflammatory markers, creating closed-loop systems that can modulate inflammatory reflexes in real-time. Companies are commercializing devices like vagus nerve stimulators and splenic nerve cuffs as drug-sparing therapies for conditions including arthritis, Crohn's disease, and sepsis.
This innovation addresses the limitations of pharmaceutical treatments for chronic inflammation and autoimmune diseases, where drugs often have side effects and may lose effectiveness over time. By using electrical stimulation to modulate the body's natural regulatory systems, bioelectronic medicine offers a potentially safer, more targeted approach that can be adjusted in real-time. Companies like SetPoint Medical, Galvani Bioelectronics, and others are developing and commercializing these devices.
The technology is particularly significant for treating chronic inflammatory conditions where long-term drug use is problematic, potentially providing effective treatment with fewer side effects. As the technology improves and more devices are approved, it could become a standard approach for treating certain conditions. However, ensuring long-term safety, optimizing stimulation parameters, and demonstrating effectiveness in clinical trials remain challenges. The technology represents an important new modality for treating disease, but requires continued development and clinical validation. Success could transform treatment of chronic inflammatory and autoimmune conditions by providing drug-free or drug-sparing alternatives, but the field is still relatively early and requires more research to understand optimal applications and parameters.
